

Edgar Filing: Edge Therapeutics, Inc. - Form S-8

Edge Therapeutics, Inc.

Form S-8

March 02, 2018

As filed with the Securities and Exchange Commission on March 2, 2018.

Registration No. 333

---

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

---

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

---

Edge Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

|                          |   |                                      |
|--------------------------|---|--------------------------------------|
| Delaware                 | 300 Connell Drive, Suite 4000<br>Berkeley Heights, NJ 07922 | 26-4231384                           |
| (State of Incorporation) | (Address of principal executive offices)<br>(Zip Code)      | (I.R.S. Employer Identification No.) |

NON-QUALIFIED STOCK OPTION INDUCEMENT AWARD

---

(Full Title of the Plan)

Brian A. Leuthner  
President and Chief Executive Officer  
Edge Therapeutics, Inc.  
300 Connell Drive, Suite 4000  
Berkeley Heights, NJ 07922  
(Name and address of agent for service)

(800) 208-3343  
(Telephone number, including area code, of agent for service)

Copies of all communications to:

|   |  |
|---|--|
| W. Bradford Middlekauff, Esq.<br>Senior Vice President, General Counsel and Secretary<br>Edge Therapeutics, Inc.<br>300 Connell Drive, Suite 4000<br>Berkeley Heights, NJ 07922 | David S. Rosenthal, Esq.<br>Dechert LLP<br>1095 Avenue of the Americas<br>New York, NY 10036<br>(212) 698-3500 |
|---|--|

Edgar Filing: Edge Therapeutics, Inc. - Form S-8

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934, as amended. (Check one):

|                         |   |                           |
|-------------------------|---|---------------------------|
| Large accelerated filer |   | Accelerated filer         |
| Non-accelerated filer   | (Do not check if a smaller reporting company) | Smaller reporting company |
| Emerging Growth Company |   |                           |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the “Securities Act”).

---

CALCULATION OF REGISTRATION FEE

| Title of securities to be registered  | Amount to be registered | Proposed maximum offering price per share | Proposed maximum aggregate offering price | Amount of registration fee |
|---|-------------------------|---|---|----------------------------|
| Common Stock of Edge Therapeutics, Inc.,<br>par value \$0.00033 per share (" <u>Common Stock</u> ") | 200,000(1 )             | \$ 10.73(2 )                              | \$ 2,146,000(2 )                          | \$ 268                     |

Represents 200,000 shares of Common Stock of Edge Therapeutics, Inc. (the "Registrant") that are issuable upon the exercise of non-qualified stock option awards granted to Andrew Saik on November 1, 2017 with a per share exercise price of \$10.73, (the "Inducement Award"). Pursuant to Rule 416 of the Securities Act, this registration (1) statement (this "Registration Statement") shall also cover any additional shares of Common Stock which become issuable under the Inducement Award by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of the outstanding shares of Common Stock.

(2) Pursuant to Rule 457(h) of the Securities Act, the offering price is estimated solely for the purpose of calculating the registration fee on the basis of the price at which the non-qualified stock option may be exercised.

## EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) by the Registrant to register shares of Common Stock issuable upon exercise of the options granted pursuant to the Inducement Award, as described below. To induce the individual listed below to accept employment with the Registrant, the Registrant granted the Inducement Award on the date detailed below:

a non-qualified stock option to purchase 200,000 shares of Common Stock of the Registrant granted to Andrew Saik on November 1, 2017.

The Inducement Award was approved by the Registrant’s Board of Directors (or a committee thereof) in compliance with and in reliance on NASDAQ Listing Rule 5635(c)(4). The Inducement Award was granted outside of the Edge Therapeutics, Inc. 2014 Equity Incentive Plan.

## PART I

### INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

Information required in Part I of Form S-8 to be contained in a prospectus meeting the requirements of Section 10(a) of the Securities Act is not required to be filed with the Commission and is omitted from this Registration Statement in accordance with the explanatory note to Part I of Form S-8 and Rule 428 under the Securities Act.

## PART II

### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

#### Item 3. Incorporation of Documents by Reference.

The following documents, as originally filed with the Commission by the Registrant, are incorporated herein by reference:

- (a) the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Commission on March 1, 2018 pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which contain the Registrant’s audited financial statements for the latest fiscal year for which such statements have been filed;
- (b) the description of the Registrant’s Common Stock, contained in its registration statement on Form 8-A, which was filed with the Commission on September 25, 2015; and
- (c) all reports and other documents hereafter filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, but prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, will be deemed to be incorporated by reference in this Registration Statement (other than current reports or portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K).

Each document incorporated by reference into this Registration Statement shall be deemed to be a part of this Registration Statement from the date of the filing of such document with the Commission, until the information contained in such document is superseded or updated by any subsequently filed document which is incorporated by reference into this Registration Statement.

Item 4. Description of Securities.

Not applicable.

---

Item 5. Interests of Named Experts and Counsel.

Not applicable.

Item 6. Indemnification of Directors and Officers.

The Registrant is incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person was an officer, director, employee or agent of such corporation, or is or was serving at the request of such person as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation's best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys' fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation's best interests except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses which such officer or director has actually and reasonably incurred. The Registrant's certificate of incorporation and bylaws provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware General Corporation Law.

Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any:

- transaction from which the director derives an improper personal benefit;
- act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
- unlawful payment of dividends or redemption of shares; or
- breach of a director's duty of loyalty to the corporation or its stockholders.

The Registrant's certificate of incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding in advance of its final disposition shall be paid by the Registrant upon delivery to the Registrant of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the Registrant.

As permitted by the Delaware General Corporation Law, the Registrant has entered into and intends to enter into indemnification agreements with each of its directors and executive officers. These agreements, among other things, require the Registrant to indemnify each director and officer to the fullest extent permitted by law and advance

expenses to each indemnitee in connection with any proceeding in which indemnification is available.

---

## Edgar Filing: Edge Therapeutics, Inc. - Form S-8

At present, there is no pending litigation or proceeding involving any of the Registrant's directors or executive officers as to which indemnification is required or permitted, and the Registrant is not aware of any threatened litigation or proceeding that may result in a claim for indemnification.

The Registrant has an insurance policy covering its officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act or otherwise.

### Item 7. Exemption from Registration Claimed.

Not applicable.

### Item 8. Exhibits.

See Exhibit Index

### Item 9. Undertakings

(a) The Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement; and

(iii) to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

provided, however, that paragraphs (a)(1)(i) and (a)(2)(ii) do not apply if the information required to be included in a post-effective amendment of this Registration Statement by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Exchange Act) that



is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

---

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

---

Exhibit Index

Exhibit

Number Description

4.1 Eighth Amended and Restated Certificate of Incorporation of Edge Therapeutics, Inc. (filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on October 6, 2015, and incorporated by reference herein).

4.2 Second Amended and Restated Bylaws of Edge Therapeutics, Inc. (filed as Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed with the Commission on October 6, 2015, and incorporated by reference herein).

4.3 Form of Certificate of Common Stock (filed as Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 filed with the Commission on September 21, 2015, and incorporated by reference herein).

4.4 Edge Therapeutics, Inc. 2014 Equity Incentive Plan (filed as Exhibit 10.4 to the Registrant's Registration Statement on Form S-1 filed with the Commission on September 21, 2015, and incorporated by reference herein).

4.5 Form of Edge Therapeutics, Inc. Executive Stock Option Agreement (filed as Exhibit 10.17 to the Registrant's Annual Report on Form 10-K filed with the Commission on March 2, 2017, and incorporated by reference herein).

4.6 Form of Edge Therapeutics, Inc. Employee Stock Option Agreement (filed as Exhibit 10.18 to the Registrant's Annual Report on Form 10-K filed with the Commission on March 2, 2017, and incorporated by reference herein).

5.1 Opinion of Dechert LLP (counsel to the Registrant) as to the legality of the securities being registered.

23.1 Consent of KPMG LLP.

23.2 Consent of Dechert LLP (included in Exhibit 5.1).

24.1 Power of Attorney (contained on the signature page hereto).

---

SIGNATURES

The Registrant. Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Berkeley Heights, State of New Jersey, on this 2nd day of March, 2018.

EDGE THERAPEUTICS, INC.

By: /s/ Brian A. Leuthner

Brian A. Leuthner

President and Chief Executive Officer

POWER OF ATTORNEY

KNOW TO ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brian A. Leuthner, Andrew Saik and W. Bradford Middlekauff, and each or any one of them, as such person's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto, with the Commission, granting unto such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary in connection with such matters and hereby ratifying and confirming all that each such attorney-in-fact, or his agent or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

| Signature   | Title   | Date          |
|---|---|---------------|
| <u>/s/ Brian A. Leuthner</u><br>Brian A. Leuthner         | President and Chief Executive Officer and Director<br>(Principal Executive Officer) | March 2, 2018 |
| <u>/s/ Andrew Saik</u><br>Andrew Saik                     | Chief Financial Officer<br>(Principal Financial Officer)                            | March 2, 2018 |
| <u>/s/ Albert N. Marchio, II</u><br>Albert N. Marchio, II | Chief Accounting and Administrative Officer<br>(Principal Accounting Officer)       | March 2, 2018 |
| <u>/s/ Sol Barer</u><br>Sol Barer                         | Chairman, Board of Directors  | March 2, 2018 |
| <u>/s/ Isaac Blech</u><br>Isaac Blech                     | Vice Chairman, Board of Directors   | March 2, 2018 |
| <u>/s/ Kurt Conti</u><br>Kurt Conti                       | Director  | March 2, 2018 |
| <u>/s/ Rosemary A. Crane</u><br>Rosemary A. Crane         | Director  | March 2, 2018 |

/s/ James I. Healy  
James I. Healy

Director

March 2, 2018

---

Edgar Filing: Edge Therapeutics, Inc. - Form S-8

|   |                                       |                  |
|---|---------------------------------------|------------------|
| <u>/s/ James Loughlin</u><br>James Loughlin       | Director                              | March 2,<br>2018 |
| <u>/s/ R. Loch Macdonald</u><br>R. Loch Macdonald | Chief Scientific Officer and Director | March 2,<br>2018 |
| <u>/s/ Liam Ratcliffe</u><br>Liam Ratcliffe       | Director                              | March 2,<br>2018 |
| <u>/s/ Robert Spiegel</u><br>Robert Spiegel       | Director                              | March 2,<br>2018 |

---